Clinical Trials | February 28, 2026
Merck’s KEYTRUDA shows significant survival boost in platinum-resistant ovarian cancer
KEYTRUDA had previously met its primary endpoint of progression-free survival in all patients
KEYTRUDA had previously met its primary endpoint of progression-free survival in all patients
The deal was executed via a merger of Novartis’ wholly owned subsidiary, Ajax Acquisition Sub, Inc., into Avidity
The initiative, funded entirely under the company’s CSR programme, is expected to reach over a million lives
The company said the move applies to all doses and reflects its commitment to making its medicines more affordable for patients
CagriSema produced a 23% weight loss at 84 weeks, versus 25.5% for tirzepatide
The program offers selected participants advanced access to Promise Bio’s broad-epiproteomic platform
The funding comes under the AHG Catalysing Innovation Awards, part of the Addiction Healthcare Goals programme led by the Office for Life Sciences
The move follows encouraging Phase I data and a series of regulatory wins from the U.S. Food and Drug Administration
The MoU lays the groundwork for deep academic and research collaboration in pharmaceutical technologies
This partnership represents a systemic shift from awareness to large-scale action for 57 lakh children
Subscribe To Our Newsletter & Stay Updated
